决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Treatment intensity affects immune reconstitution even after childhood cancer not treated with hematopoietic stem cell transplantation.
Treatment intensity affects immune reconstitution even after childhood cancer not treated with hematopoietic stem cell transplantation.
我们的数据表明,在大多数当前儿科肿瘤治疗后,所研究的免疫学参数可快速恢复。针对高危急性淋巴细胞白血病、急性髓系白血病、髓母细胞瘤和成熟B细胞淋巴瘤的治疗,与相当比例病例的免疫恢复时间延长相关。高治疗强度与免疫恢复延长相关。
只有少数先前的研究考察了完成癌症治疗后的免疫系统恢复情况。
本研究旨在分析儿童肿瘤治疗后在非造血干细胞移植情况下的免疫重建。
我们分析了2014年至2019年在芬兰图尔库大学医院诊断为癌症并接受化疗联合或不联合放疗的儿童(N = 79)。我们回顾性收集了基线参数和治疗后免疫恢复的数据,即中性粒细胞和淋巴细胞计数、IgG水平、CD19、CD4和NK 细胞计数。免疫学参数随访至其恢复正常。治疗强度根据治疗强度评定量表(ITR-3)进行分层。我们分析了治疗强度对整个治疗范围内免疫学参数恢复正常的影响。治疗强度对治疗完成后的免疫系统恢复有重大影响。大多数患者在高强度和低强度治疗组中治疗后1-4个月免疫学参数均正常,但被归类为高强度组的患者比低强度组的患者更常出现参数偏低。
BACKGROUND: Only a few previous studies examine immune system recovery after completed cancer treatment. AIMS: The aim of this study was to analyze immune reconstitution after childhood cancer therapy in a non-hematopoietic stem cell transplantation setting. METHODS AND RESULTS: We analyzed children (N = 79) who received chemotherapy with/without irradiation for cancer diagnosed between 2014 and 2019 at Turku University Hospital, Finland. We retrospectively collected data on baseline parameters and post-treatment immunological recovery, namely neutrophil and lymphocyte counts, IgG levels, CD19, CD4 and natural killer cell counts. Immunological parameters were followed until their normalization. Treatment intensity was stratified according to the Intensity of Treatment Rating Scale (ITR-3). We analyzed the effects of treatment intensity on normalization of immunological parameters across the entire treatment range. Treatment intensity had a major effect on immune system recovery after completion of treatment. Most patients had normal immunological parameters 1-4 months post-treatment both in high- and low-intensity treatment groups, but patients classified in the high-intensity group had low parameters more often than patients in the low-intensity group. CONCLUSION: Our data suggest a fast recovery of studied immunological parameters after the majority of current pediatric oncologic treatments. Treatment for high-risk acute lymphoblastic leukemia, acute myeloid leukemia, medulloblastoma, and mature B-cell lymphoma was associated with prolonged recovery times for a substantial proportion of cases. High treatment intensity was associated with prolonged immunological recovery.
MEMBER ACCOUNT
登录成功会直接打开下一页。